Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

niddapharm gmbh - hepatitis a-virus, stamm rg-sb, inaktiviert - suspension zur injektion - hepatitis a-virus, stamm rg-sb, inaktiviert >= 500.ria-units

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

kohlpharma gmbh - hepatitis a-virus, stamm rg-sb, inaktiviert - suspension zur injektion - hepatitis a-virus, stamm rg-sb, inaktiviert >= 24.i.e.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - hepatitis b immunoglobulin, quantity: 400 iu; human immunoglobulin g, quantity: 160 mg/ml - injection, solution - excipient ingredients: glycine; water for injections; human immunoglobulin a - hepatitis b immunoglobulin-vf is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis b antibody level is inadequate (<10iu/l). post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to hbsag-positive or suspected hbsag-positive material, for example, by needle stick, oral ingestion or sexual exposure. hepatitis b immunoglobulin-vf is also indicated for prophylaxis in infants born to hbsag-positive mothers.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - hepatitis b immunoglobulin, human 160 mg/ml ((>= 98% )as human plasma proteins (exnz)) - solution for injection - 100 iu - active: hepatitis b immunoglobulin, human 160 mg/ml ((>= 98% )as human plasma proteins (exnz)) excipient: glycine water for injection - hepatitis b immunoglobulin-vf is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis b antibody level is inadequate (< 10 iu/l). post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to hbsag-positive or suspected hbsag-positive material, for example, by needle stick, oral ingestion or sexual exposure. hepatitis b immunoglobulin-vf is also indicated for prophylaxis in infants born to hbsag-positive mothers.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - hepatitis b immunoglobulin, human 160 mg/ml (( >= 98%) as human plasma proteins (ex nz)) - solution for injection - 400 iu - active: hepatitis b immunoglobulin, human 160 mg/ml (( >= 98%) as human plasma proteins (ex nz)) excipient: glycine water for injection - hepatitis b immunoglobulin-vf is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis b antibody level is inadequate (< 10 iu/l). post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to hbsag-positive or suspected hbsag-positive material, for example, by needle stick, oral ingestion or sexual exposure. hepatitis b immunoglobulin-vf is also indicated for prophylaxis in infants born to hbsag-positive mothers.

Tyrkia - tyrkisk - TİTCK (Türkİye İlaç Ve Tibbİ Cİhaz Kurumu)

merck sharp dohme İlaÇlari ltd. Ştİ. - inaktif hepatit a virusu (cr 326f susu) -

Tyrkia - tyrkisk - TİTCK (Türkİye İlaç Ve Tibbİ Cİhaz Kurumu)

merck sharp dohme İlaÇlari ltd. Ştİ. - inaktif hepatit a virusu (cr 326f susu) -

Kenya - engelsk - Pharmacy and Poisons Board

serum institute of india ltd. 212/2 hadapsar pune 411028 india - hepatitis b vaccine (rdna) (adult) - suspension for injection - each dose of 1 ml contains purified hepatitis b… - viral vaccines: hepatitisvaccines

Kenya - engelsk - Pharmacy and Poisons Board

serum institute of india ltd. 212/2 hadapsar pune 411028 india - hepatitis b vaccine (rdna) (paediatric) - suspension for injection - each dose of 0.5 ml contains purified hepatitis… - viral vaccines: hepatitisvaccines

Tyskland - tysk - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

emra-med arzneimittel gmbh - salmonella typhi (stamm ty 2) vi-kapselpolysaccharid, hepatitis a-virus, stamm gbm, inaktiviert - lösung und suspension zur injektion - salmonella typhi (stamm ty 2) vi-kapselpolysaccharid 25.µg; hepatitis a-virus, stamm gbm, inaktiviert 160.atg-e